TGFB2 and age-related macular degeneration: The comparison of active TGF-β2 and TGF-β3 concentrations between patients and controls, revealed that baseline (naïve AMD) and month 1 (Treat.1) concentrations of active TGF-β2 were lower than in controls (controls mean ± SD = 214.2 ± 90.37 pg/mL; baseline AMD mean = 151.4 ± 63.6 pg/mL; month 1 mean = 157.3 ± 71.0 pg/mL), while the month 2 (Treat.2) value was lower, albeit not significantly, than the control value (month 2 mean = 170.7 ± 60.2 pg/mL) (Fig. 2a).